<DOC>
	<DOCNO>NCT02201056</DOCNO>
	<brief_summary>The purpose study characterize safety tolerability profile TAK-935 healthy participant administer single dose oral solution escalate dose level .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Escalating Single Doses TAK-935</brief_title>
	<detailed_description>The drug test study TAK-935 . TAK-935 test find safe well-tolerated dose assess TAK-935 process body . This study look side effect lab result people take TAK-935 design randomize dose-rising study . The study consist 6 Cohorts 8 participant Cohort . In Cohort , 6 participant receive single dose TAK-935 2 participant receive placebo 10-hour fast . The start dose 15 mg follow planned dos 50 , 200 , 600 , 900 exceed 1350 mg subsequent cohort . This single-center trial conduct United States . The overall time participate study 51 day . Participants make 2 visit clinic , include one 7-day period confinement clinic . All participant contact telephone 14 day dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Is healthy male female adult 19 55 year age inclusive time inform consent . 2 . Weighs least 45 kg body mass index ( BMI ) 18.0 30.0 kg/m^2 , inclusive Screening Visit . 1 . Has uncontrolled , clinically significant neurological ( include seizure disorder ) , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urological , immunologic , endocrine disease , psychiatric disorder , abnormality . 2 . Has know hypersensitivity component formulation TAK935 . 3 . There find participant 's medical history , significant result physical examination , safety laboratory test .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>